This study is accepting new patients by invitation only
Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)
Summary
- Eligibility
- for males (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jonathan Strober
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jonathan Strober
Professor, Neurology, School of Medicine. Authored (or co-authored) 60 research publications
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- PTC Therapeutics
- Links
- PTC Therapeutics, Inc website Protocol V7.0
- ID
- NCT01247207
- Phase
- Phase 3 Duchenne Muscular Dystrophy Research Study
- Study Type
- Interventional
- Participants
- Expecting 270 study participants
- Last Updated